基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价

doi:10.19803/j.1672-8629.2022.02.20

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (2): 205-209.
DOI: 10.19803/j.1672-8629.2022.02.20

基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价

周瑞欧¹, 季欢欢¹, 龚莉², 张妮², 宋林^1,*

¹重庆医科大学附属儿童医院药学部,儿童发育疾病研究教育部重点实验室,国家儿童健康与疾病临床医学研究中心,儿童发育重大疾病国家国际科技合作基地,儿科学重庆市重点实验室,重庆 400014;
²重庆医科大学药学院,重庆 400016

收稿日期:2020-04-17 出版日期:2022-02-15 发布日期:2022-02-15
通讯作者: ^*宋林,女,博士,副主任药师,药物警戒与医院药学。E-mail：songlin0409@sina.com
作者简介:周瑞欧,男,本科,主管药师,临床药学。
基金资助:
重庆市教委智慧医学—智慧药学（ZHYX2019022）

Detection and evaluation of adverse event signals of ribavirin, lopinavir / ritonavir and chloroquine phosphate based on FAERS database

ZHOU Ruiou¹, JI Huanhuan¹, GONG Li², ZHANG Ni², SONG Lin^1,*

¹Department of Pharmacy; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics; Children's Hospital of Chongqing Medical University, Chongqing 400014, China;
²School of Pharmacy, Chongqing Medical University, Chongqing 400016, China

Received:2020-04-17 Online:2022-02-15 Published:2022-02-15

摘要/Abstract

摘要： 目的挖掘和评价利巴韦林、洛匹那韦/利托那韦（LPV/r）、磷酸氯喹上市后安全信号,为临床合理用药提供参考。方法采用报告比值比法（ROR）对美国食品药品监督管理局（FDA）不良事件报告系统（FAERS）2004年1月1日至2019年12月31日收录的不良事件报告进行信号挖掘,重点分析3种目标药物上报频数前30位药品不良事件（ADE）信号及特定医学事件（designated medical event, DME）信号。结果 3种目标药物上报频数前30位ADE较为相似,利巴韦林以血液系统毒性信号较显著,LPV/r以肝毒性、免疫重建炎症综合征信号较显著,磷酸氯喹以心脏毒性、眼毒性信号较显著;三者DME共性信号为肝衰竭、溶血症、溶血性贫血、骨髓功能衰竭、Steven-Johnson综合征等。结论基于真实世界自发上报数据库的ADE信号检测有助于利巴韦林、LPV/r、磷酸氯喹的安全性评价,降低临床用药风险。

关键词: 药品不良事件, 利巴韦林, 洛匹那韦/利托那韦, 磷酸氯喹, 信号检测

Abstract: Objective To mine and evaluate the safety signals of ribavirin, lopinavir/ ritonavir, chloroquine phosphate and to provide reference for clinical rational drug use. Methods The reporting odd ratio (ROR) data mining algorithm was used to investigate ADE risk signals from FAERS submitted to the FDA between January 1, 2004 and December 31, 2019. The top 30 reporting ADE and designated medical event (DME) signals were the focus of analysis. Results The top 30 ADEs of the three target drugs were similar. What was more significant was the signals from the hematological toxicity of ribavirin, the hepatotoxicity, cardiac toxicity and immune reconstitution inflammatory syndrome of lopinavir / ritonavir and from the cardiotoxicity and ocular toxicity of chloroquine phosphate. The common DME signals of the three drugs were involved in liver failure, hemolysis, hemolytic anemia, bone marrow failure and Steven-Johnson syndrome. Conclusion The detection of ADE signals based on the real-world spontaneous reporting database can contribute to safety evaluation of ribavirin, lopinavir/ritonavir, chloroquine phosphate while reducing the risk of clinical medication.

Key words: adverse drug event, ribavirin, lopinavir/ritonavir, chloroquine phosphate, signal detection

中图分类号:

R979.9

周瑞欧, 季欢欢, 龚莉, 张妮, 宋林. 基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价[J]. 中国药物警戒, 2022, 19(2): 205-209.

ZHOU Ruiou, JI Huanhuan, GONG Li, ZHANG Ni, SONG Lin. Detection and evaluation of adverse event signals of ribavirin, lopinavir / ritonavir and chloroquine phosphate based on FAERS database[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 205-209.

参考文献

[1] GONG L, PAN LY, LIU Y, et al.Detection and evaluation of post-marketing safety alert signals for human papillomavirus 9-valent vaccine based on US vaccine adverse event reporting system (VAERS)[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2019, 16(8): 478-486.
[2] MOORE NF, BEGAUD TB.The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2005, 14(4): 285-286.
[3] BATE A, EVANS SJ.Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Safety, 2009, 18(6): 427-436.
[4] LIANG B, ZHOU C.Clinical research and development of new drugs-analysis of the principle of safety evaluation[J]. Journal of Pharmaceutical Epidemiology(药物流行病学杂志),2013, 22(1): 35-39.
[5] LI QF, LIU H, ZHANG DD, et al.Analysis and suggestions on risk of ribavirin in children[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(2): 83-89.
[6] LIU XT, WANG JX.Related mechanisms and countermeasures of hemolytic anemia caused by ribavirin[J]. Chinese Hepatology(肝脏), 2012, 17(11): 814-817.
[7] KEPPEKE GD, CALISE SJ, CHAN EK, et al.Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-alpha/ribavirin therapy[J]. World J Gastroenterol, 2016, 22(6): 1966-1974.
[8] HUNYADY B, KOVACS B, BATTYANI Z.Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection[J]. Orv Hetil, 2011, 152(50): 1997-2009.
[9] KASTURI KS, MUMMADI RR, SOOD GK.Neutropenic enterocolitis: An unusual complication of HCV combination therapy with PEG-IFN and ribavirin[J]. Eur J Intern Med, 2008, 19(5): 372-373.
[10] JACKOWIAK E, SHAH N, CHEN H, et al.A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: clinical, pathological, and radiographic features[J]. Transpl Infect Dis, 2019, 21(5): e13162-e13168.
[11] CALZA L, TRAPANI F, SALVADORI C, et al.Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir[J]. Scand J Infect Dis, 2013, 45(2): 147-154.
[12] MANON VAN DER LRS, EMILE S. Pharmac-okinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients[J]. Antiviral Therapy, 2007, 12(7): 1127-1132.
[13] Society European AIDS Clinical. 2019 European AIDS clinical society guidelines version 10.0 [EB/OL]. (2019-11-08) [2020-03-02]. http://guide.medlive.cn/guideline/19262.
[14] YUSUF IH, SHARMA S, LUQMANI R, et al.Hydroxychloroquine retinopathy[J]. Eye (Lond), 2017, 31(6): 828-845.
[15] CHATRE C, ROUBILLE F, VERNHET H, et al.Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature[J]. Drug Saf, 2018, 41(10): 919-923.

基于FAERS数据库对利巴韦林、洛匹那韦/利托那韦、磷酸氯喹不良事件检测与评价

Detection and evaluation of adverse event signals of ribavirin, lopinavir / ritonavir and chloroquine phosphate based on FAERS database

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈枭, 郭晓晶, 许金芳, 韦连慧, 陈晨鑫, 梁际洲, 郑轶, 叶小飞. 机器学习方法在FAERS布加替尼不良反应信号检测中的应用[J]. 中国药物警戒, 2023, 20(6): 639-645.
[2]	韦连慧, 张朋朋, 刘永梅, 郭晓晶, 许金芳, 陈枭, 陈晨鑫, 叶小飞. 重叠加权法在药品不良反应信号检测中的模拟研究[J]. 中国药物警戒, 2023, 20(6): 646-650.
[3]	陈晨鑫, 张朋朋, 刘永梅, 叶小飞, 贺佳. 零膨胀模型与狄利克雷过程结合在药品上市后不良反应信号检测中的应用[J]. 中国药物警戒, 2023, 20(6): 651-654.
[4]	陈亚昆, 门鹏, 王攀. 基于FAERS数据库的4种磷酸二酯酶5抑制剂安全性分析[J]. 中国药物警戒, 2023, 20(6): 691-696.
[5]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[6]	郝晓慧, 张萍, 武璐璐, 王丽华. 基于FAERS数据库的枸橼酸伊沙佐米胶囊安全信号挖掘研究[J]. 中国药物警戒, 2023, 20(12): 1427-1431.
[7]	张玄羿, 孔文强, 钟红, 邓慧远, 舒云峰. 基于FAERS数据库挖掘阿比特龙不良事件信号研究[J]. 中国药物警戒, 2023, 20(10): 1148-1153.
[8]	钱佩佩, 曹凯, 徐炳欣, 应亚宾, 赵宁珂, 赵亮. 基于JADER数据库的奈玛特韦/利托那韦不良事件信号检测与分析[J]. 中国药物警戒, 2023, 20(10): 1154-1158.
[9]	张敬升, 高双荣, 庞博, 包蕾, 孙静, 陈梦苹, 徐英莉, 曹姗, 郭姗姗, 赵荣华, 崔晓兰. 金振口服液对流感病毒H1N1/FM1株和副流感病毒感染致小鼠肺炎的药理作用[J]. 中国药物警戒, 2023, 20(1): 46-51.
[10]	李美云, 唐广良, 陈志宏, 何鑫, 陈沈珏, 李昕, 刘丽华. 107例利巴韦林不良反应分析[J]. 中国药物警戒, 2022, 19(7): 770-774.
[11]	王铁柱. 硫酸羟氯喹致视觉损害不良反应信号检测与分析[J]. 中国药物警戒, 2022, 19(6): 657-660.
[12]	张弛. PCSK9抑制剂阿利罗库单抗不良事件信号发掘[J]. 中国药物警戒, 2022, 19(6): 684-691.
[13]	杨淼, 杨莉, 赵志刚. 利巴韦林在我国7个城市儿科应用现状与合理应用评价[J]. 中国药物警戒, 2022, 19(4): 408-412.
[14]	陈超, 赵云飞, 王长之, 龚立雄, 刘伟. 乌普萨拉监测中心vigiRank预测模型研究[J]. 中国药物警戒, 2022, 19(3): 270-274.
[15]	周博雅, 袁偲偲, 冯欣. 哺乳期女性服用洛匹那韦/利托那韦对乳儿影响的研究进展[J]. 中国药物警戒, 2022, 19(3): 296-301.